The extended patent for tigecycline injection can have significant implications for pricing. When a patent is extended, it grants the patent holder exclusive rights to manufacture and sell the drug for an extended period beyond the initial patent term. This exclusivity allows the manufacturer to maintain a monopoly on the drug, limiting competition from generic versions and potentially keeping prices higher than they would be if generic alternatives were available [3].

In the case of tigecycline injection, the extended patent term provides the manufacturer with an extended period of market exclusivity, which can delay the entry of generic competitors into the market. This lack of competition can result in higher prices for the drug, as the manufacturer can continue to set prices without the pressure of generic alternatives [1].

It is essential to note that while patent extensions can lead to higher prices for the drug, they also play a crucial role in incentivizing innovation by providing pharmaceutical companies with the opportunity to recoup their research and development costs. This balance between incentivizing innovation and ensuring access to affordable medications is a complex issue that requires careful consideration [2].

Overall, the extended patent for tigecycline injection can impact pricing by maintaining market exclusivity and limiting competition, potentially resulting in higher prices for the drug.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/EXTENDED
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037176/
[3] https://www.uspto.gov/patents/laws/patent-term-extension/patent-terms-extended-under-35-usc-156